Resistance to the approved inhibitors of KIT proto-oncogene, receptor tyrosine kinase (KIT), and platelet-derived growth factor receptor α (PDGFRA) is a serious clinical challenge for patients with advanced gastrointestinal stromal tumors. Here, PDGFRA is linked to gastrointestinal stromal tumor.